Biosimilars Show Their Muscle as Emerging Pharmaceutical Phenomenon
Biosimilars Show Their Muscle as Emerging Pharmaceutical Phenomenon
Attachment: Biosimilar Heat Map, May 2018
SUGAR LAND--May 17, 2018--Researched by Industrial Info Resources (Sugar Land, Texas)--Almost the same, but not quite--a biosimilar is just that, similar but not equal to an original biological drug. Unlike generics, biological drugs are too complex be duplicated. And the market for biosimilars is definitely worth watching. Industrial Info is tracking nearly $2 billion worth of active biosimilar facility projects worldwide.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market